La traducción aún no está lista. Se muestra el artículo original.
(RTTNews) - MaxCyte, Inc. (MXCT) has entered into a definitive agreement to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management for total consideration of $151.8 million. At the close of the transaction, MaxCyte will pay $105.0 million in cash, subject
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.